The 4 most recent market catalysts affecting $MRVI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5
Wells Fargo analyst Evan Stampler maintained an 'Overweight' rating on Maravai LifeSciences and raised the price target from $5.50 to $6.50. This action signals continued confidenc…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 55
Maravai LifeSciences Affirms FY2026 Sales Guidance of $205.000M-$215.000M vs $210.433M Est
Maravai LifeSciences (MRVI) filed an 8-K to affirm its previously stated FY2026 sales guidance of $205 million to $215 million. This is significant because it indicates that the co…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 65
Maravai LifeSciences Q2 Adj. EPS $(0.02) Beats $(0.04) Estimate, Sales $51.442M Beat $48.682M Estimate
This headline is a positive corporate catalyst for Maravai LifeSciences (MRVI). Beating both EPS and sales estimates, even with a negative adjusted EPS, suggests the company is per…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 55
Maravai LifeSciences' TriLink BioTechnologies Obtains New Patent From The China National Intellectual Property Administration, Patent Number ZL 2025 1 1246578.X
Maravai LifeSciences' subsidiary, TriLink BioTechnologies, has secured a new patent in China for its RNA synthesis methods, including its CleanCap technology. This is significant b…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.